Johnson & Johnson (J&J) has entered into a denitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to $1.125 billion.

Buying a membership today will give you:
To continue reading this article register now.